 DARTMOUTH, Nova Scotia--BUSINESS WIRE--IMV Inc. the Company or IMV TSX: IMV; NASDAQ: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021. We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, 